scholarly journals Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid

2003 ◽  
Vol 88 (11) ◽  
pp. 5287-5292 ◽  
Author(s):  
G. Brenta ◽  
M. Schnitman ◽  
O. Fretes ◽  
E. Facco ◽  
M. Gurfinkel ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Side Effects ◽  
Bone Mineral ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Thyroid Volume ◽  
Mineral Density ◽  
Free T4 ◽  
Chronic Thyroiditis ◽  
Femoral Bone Mineral Density

Abstract Euthyroid goiter is usually treated with TSH-inhibitory doses of levo-T4 (l-T4). Because triiodothyroacetic acid (TRIAC) decreases TSH levels, the following study was perfomed: 36 euthyroid goitrous female patients (no cancer or chronic thyroiditis) were randomized to TRIAC (19.6 μg/kg) (n = 19) or l-T4 (1.7 μg/kg) (n = 17) treatment during 11 months. Goiter volume; lumbar and femoral bone mineral density; serum osteocalcin; deoxypyridinoline; TSH; free T4; total, high-density lipoprotein, and low-density lipoprotein cholesterol; and triglycerides were measured before and after the study period. Student’s t test and χ2 analysis were performed. TSH values (microunits per milliliter) in the TRIAC and l-T4 groups were: 1.91 ± 0.6 (basal) and 0.180 ± 0.1 (after) and 2.1 ± 2.5 (basal) and 0.180 ± 0.3 (after), respectively. Thyroid volume decreased 37.9 ± 35.4% in the TRIAC patients and 14.5 ± 39.5% in the l-T4 group (P = 0.069). Forty-two percent of the goiters with TRIAC reduced more than 50% their initial volume vs. 17.7% with l-T4 (P = 0.15). With TRIAC, patients experienced fewer side effects. No differences in the changes of bone mineral density, serum deoxypyridinoline, osteocalcin, or the lipid profile were observed between both groups. The present results show that TRIAC is more effective than l-T4 in the reduction of goiter size, with comparable effects on peripheral parameters.

Detection of Vascular Disease Risk in Women by Panoramic Radiography

2003 ◽  
Vol 82 (10) ◽  
pp. 838-843 ◽  
Author(s):  
A. Taguchi ◽  
Y. Suei ◽  
M. Sanada ◽  
Y. Higashi ◽  
M. Ohtsuka ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Disease Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Vascular Diseases ◽  
Mineral Density ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Skeletal Bone

Low bone mineral density and rapid bone loss of the skeleton are associated with mortality risk from vascular diseases in post-menopausal women. Panoramic radiographic measurements are considered as indicators of skeletal bone mineral density or bone turnover. We hypothesize that such measurements may be associated with vascular disease risk in post-menopausal women. Associations of mandibular cortical shape and width on panoramic radiographs with skeletal bone mineral density and risk factors related to vascular diseases were investigated in 87 post-menopausal women. Cortical shape was associated with skeletal bone mineral density, low-density lipoprotein cholesterol, apolipoprotein B, resting heart rate, and endothelial dysfunction. Cortical width was associated with skeletal bone mineral density, low-density lipoprotein cholesterol, and apolipoprotein A1. Dentists may be able to refer women with increased risk of vascular diseases, as well as low bone mineral density, to medical professionals for further examination by panoramic findings.

scholarly journals Prevalence of Surrogate Markers of Relative Energy Deficiency in Male Norwegian Olympic-Level Athletes

2021 ◽  
Vol 31 (6) ◽  
pp. 497-506
Author(s):  
Thomas Birkedal Stenqvist ◽  
Anna Katarina Melin ◽  
Ina Garthe ◽  
Gary Slater ◽  
Gøran Paulsen ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Relative Energy ◽  
Low Density ◽  
Mineral Density ◽  
Free Triiodothyronine ◽  
Energy Deficiency ◽  
Low Testosterone

The syndrome of Relative Energy Deficiency in Sport (RED-S) includes wide-ranging effects on physiological and psychological functioning, performance, and general health. However, RED-S is understudied among male athletes at the highest performance levels. This cross-sectional study aimed to investigate surrogate RED-S markers prevalence in Norwegian male Olympic-level athletes. Athletes (n = 44) aged 24.7 ± 3.8 years, body mass 81.3 ± 15.9 kg, body fat 13.7% ± 5.8%, and training volume 76.1 ± 22.9 hr/month were included. Assessed parameters included resting metabolic rate (RMR), body composition, and bone mineral density by dual-energy X-ray absorptiometry and venous blood variables (testosterone, free triiodothyronine, cortisol, and lipids). Seven athletes (16%) grouped by the presence of low RMR (RMRratio < 0.90) (0.81 ± 0.07 vs. 1.04 ± 0.09, p < .001, effect size 2.6), also showed lower testosterone (12.9 ± 5.3 vs. 19.0 ± 5.3 nmol/L, p = .020) than in normal RMR group. In low RMRratio individuals, prevalence of other RED-S markers (—subclinical—low testosterone, low free triiodothyronine, high cortisol, and elevated low-density lipoprotein) was (N/number of markers): 2/0, 2/1, 2/2, 1/3. Low bone mineral density (z-score < −1) was found in 16% of the athletes, all with normal RMR. Subclinical low testosterone and free triiodothyronine levels were found in nine (25%) and two (5%) athletes, respectively. Subclinical high cortisol was found in 23% of athletes while 34% had elevated low-density lipoprotein cholesterol levels. Seven of 12 athletes with two or more RED-S markers had normal RMR. In conclusion, this study found that multiple RED-S markers also exist in male Olympic-level athletes. This highlights the importance of regular screening of male elite athletes, to ensure early detection and treatment of RED-S.

Effects of a 6-month moderate-intensity exercise program on metabolic parameters and bone mineral density in men on androgen deprivation therapy for prostate cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 237-237 ◽  
Author(s):  
Shabbir M.H. Alibhai ◽  
Sara Durbano ◽  
Meagan O'Neill ◽  
Daniel Santa Mina ◽  
Paul Ritvo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Side Effects ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Density Lipoprotein ◽  
Metabolic Parameters ◽  
Moderate Intensity ◽  
Mineral Density ◽  
Moderate Intensity Exercise

237 Background: Androgen deprivation therapy (ADT) is commonly used to treat prostate cancer (PC) but is associated with significant side effects including metabolic abnormalities and bone loss. Although multiple trials have demonstrated that exercise is associated with improvements in multiple side effects of ADT, its effects on metabolic and skeletal outcomes is unclear. We conducted a phase II randomized controlled trial (RCT) comparing three different exercise delivery models. The present analysis examined prespecified endpoints of change in metabolic parameters and bone mineral density. Methods: Men with stage TxNxMx PC starting or continuing ADT for at least 6 months were enrolled and randomized equally to personal training (n = 18), supervised group training (n = 14), or home-based training (n = 16). Participants in all intervention arms underwent moderate to vigorous physical activity with a target of 150 minutes per week for 6 months. Fasting blood work and dual x-ray absorptiometry (DXA) were done at baseline and 6 months (blood work) and 12 months (DXA). Paired t-tests and ANCOVA were used to analyze findings. Results: 48 participants (mean age 69.9 years) were enrolled. The primary analysis demonstrated no significant difference between arms on most quality of life and fitness outcomes so groups were combined for the present analysis. Exercise was not associated with statistically significant changes in hemoglobin, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, or fasting blood glucose (p = 0.075 to 0.87). Similarly, exercise was not associated with changes in bone mineral density at lumbar spine, total hip, or femoral neck sites on DXA (p = 0.44 to 0.71). Mean weight change was +0.8 kg. There was no difference between exercise arms on any outcome. Conclusions: Although our study is limited by a small sample size, our results suggest that 6 months of moderate intensity exercise is not associated with improvements in either metabolic or skeletal outcomes in men on ADT. More intensive behavioural interventions and/or pharmacological interventions will be required to reverse the deleterious effects of ADT. Clinical trial information: NCT02046837.

scholarly journals LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density

2004 ◽  
Vol 49 (2) ◽  
pp. 80-86 ◽  
Author(s):  
Takeshi Mizuguchi ◽  
Itsuko Furuta ◽  
Yukio Watanabe ◽  
Kazuhiro Tsukamoto ◽  
Hiroshi Tomita ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Lipoprotein Receptor ◽  
Related Protein ◽  
Mineral Density ◽  
Density Lipoprotein Receptor ◽  
Lipoprotein Receptor Related Protein

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease

2005 ◽  
Vol 3 (2) ◽  
pp. 113-121 ◽  
Author(s):  
Erik J. Schoon ◽  
Simona Bollani ◽  
Peter R. Mills ◽  
Eran Israeli ◽  
Dieter Felsenberg ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Crohn’S Disease ◽  
Side Effects ◽  
Crohn's Disease ◽  
Bone Mineral ◽  
Mineral Density

scholarly journals Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate

2018 ◽  
Vol 4 (1) ◽  
pp. 51-58
Author(s):  
Wilson S ◽  
Sharp CA ◽  
Davie MWJ
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Side Effects ◽  
Bone Mineral ◽  
Oral Treatment ◽  
Fracture Incidence ◽  
Mineral Density ◽  
Intravenous Pamidronate ◽  
Vertebral Fracture Incidence

Purpose: Bisphosphonates are valuable in reducing the incidence of fracture. Side effects limit persistence with oral therapy and long term studies of pain relief are difficult to pursue. Intravenous bisphosphonates offer an alternative treatment to oral bisphosphonates and are tolerated over a longer period. The use of Pamidronate, an intravenously administered bisphosphonate, to benefit pain and reduce fracture incidence in the long term has not been extensively investigated. The study aimed to investigate the effect of Pamidronate on pain, vertebral fracture incidence and Bone Mineral Density over 6 or more years.Methods: Patients were offered intravenous Pamidronate if oral treatment with bisphosphonates or Hormone replacement therapy had failed due to side effects, fractures continued on oral treatment or oesophageal reflux led to cessation of oral treatment. Pain was assessed using the Nottingham health profile; radiographs were used to evaluate vertebral fracture and DXA measured bone mineral density.Results: The primary outcome was the pain domain. Median patient follow up was 9 years. Pain had improved significantly (p = 0.03) and in 68% pain had either improved or remained unchanged. Vertebral fractures occurred in 14% of patients in the first 3 years, 9.5% in years 4-6, but increased in years 7-9 to 27%. Bone mineral density increased in the lumbar spine (p < 0.001) but not at the femoral neck.Conclusions: Pamidronate had a beneficial effect on pain over the period of the study. Vertebral fracture incidence increased after 6 years of Pamidronate, although spine BMD increased significantly.

scholarly journals The effect of plasma lipids and lipid lowering interventions on bone mineral density: a Mendelian randomization study

2018 ◽  
Author(s):  
Jie Zheng ◽  
Marie-Jo Brion ◽  
John P. Kemp ◽  
Nicole M. Warrington ◽  
Maria-Carolina Borges ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Standard Deviation ◽  
Bone Mineral ◽  
Mendelian Randomization ◽  
Causal Effect ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
Mineral Density

AbstractStatin treatment increases bone mineral density (BMD) and reduces fracture risk, but the underlying mechanism is unclear. We used Mendelian randomization (MR) to assess whether this relation is explained by a specific effect in response to statin use, or by a general effect of lipid-lowering. We utilized 400 single nucleotide polymorphisms (SNPs) robustly associated with plasma lipid levels and results from a heel BMD GWAS (derived from quantitative ultrasound) in 426,824 individuals from the UK Biobank. We performed univariate and multivariable MR analyses of low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglyceride levels on BMD. To test whether the effect of statins on BMD was mediated by lowering lipid levels, MR was repeated with and without SNPs in theHMGCRregion, the gene targeted by statins. Univariate MR analyses provided evidence for a causal effect of LDL-C on BMD (β= −0.060; −0.084 to −0.036; P = 4×10-6; standard deviation change in BMD per standard deviation change in LDL-C, with 95% CI), but not HDL or triglycerides. Multivariable MR analysis suggested that the effect of LDL-C on BMD was independent of HDL-C and triglycerides, and sensitivity analyses involving MR Egger and weighted median MR approaches suggested that the LDL-C results were robust to pleiotropy. MR analyses of LDL-C restricted to SNPs in theHMGCRregion showed similar effects on BMD(β= −0.083; −0.132 to −0.034; P = 0.001) to those excluding these SNPs (β= −0.063; −0.090 to −0.036; P = 8×10-6). Bidirectional MR analyses provided some evidence for a causal effect of BMD on plasma LDL-C levels. Our results suggest that effects of statins on BMD are at least partly due to their LDL-C lowering effect. Further studies are required to examine the potential role of modifying plasma lipid levels in treating osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document